 |
|
|
| |
HBsAg Loss With Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a in Chronic Hepatitis B: Results of a Global Randomized Controlled Trial
|
| |
| |
Reported by Jules Levin
APASL 2015
March 12-15, Istanbul, Turkey
Patrick Marcellin1, Sang-Hoon Ahn2, Xiaoli Ma3, Florin A. Caruntu4, Won-Young Tak5, Magdy Elkashab6, Wan-Long Chuang7, Fehmi Tabak8, Rajiv Mehta9, Joerg Petersen10, Eduardo B. Martins11, Phillip Dinh11,Amoreena Corsa11, Prista Charuworn11, G. Mani Subramanian11, John G. McHutchison11, Maria Buti12, Giovanni Gaeta13, George Papatheodoridis14, Robert Flisiak15, Henry L.Y. Chan16
1Hopital Beaujon, Universite Paris-Diderot, Clichy, France; 2Yonsei University College of Medicine, Seoul, South Korea; 3Drexel University College of Medicine, Philadelphia, PA; 4National Institute for Infectious Diseases "Prof Dr Matei Bals,"
Bucharest, Romania; 5Kyungpook National University Hospital, Daegu, South Korea; 6Toronto Liver Centre, Ontario, Canada; 7Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan; 8Istanbul University
Cerrahpasa Faculty of Medicine, Istanbul, Turkey; 9Liver Clinic, Surat, India; 10University of Hamburg, Germany; 11Gilead Sciences Inc., Foster City, CA; 12Hospital Universitari Vall d'Hebron, Barcelona, Spain; 13Second University of Naples, Italy; 14Athens University Medical School, Athens, Greece; 15Medical University of Bialystok, Poland; 16The Chinese University of Hong Kong, Hong Kong SAR, Peoples Republic of China
|
| |
|
|
|
|
|
